What question did this study set out to answer?

The aim is to understand resistance to anti-GD2 therapy in neuroblastoma and to evaluate GM2 as an alternative immunotherapy target.

Ganglioside Targeting as a Dual Approach to Neuroblastoma Treatment

View Full Paper

Ask AI

Bookmark

The aim is to understand resistance to anti-GD2 therapy in neuroblastoma and to evaluate GM2 as an alternative immunotherapy target.
Conducted murine models for anti-GM2 monoclonal antibodies and CAR T cell therapies.
Tested combination therapy with both GD2 and GM2 targeting.
Performed tissue distribution analysis of GM2 using immunohistochemistry.
Anti-GM2 therapy showed initial efficacy but lacked long-term responses in monotherapy.
Combination therapy led to complete tumor eradication and improved survival in murine models.
GM2 minimal distribution in normal tissues showed promise for safety in targeting alongside GD2.

No takes yet. Share an insight, caveat, or question.

This investigation demonstrates improved outcomes using GM2 and GD2 dual targeting in neuroblastoma, suggesting enhanced therapeutic strategies.

Dalton et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

This investigation demonstrates improved outcomes using GM2 and GD2 dual targeting in neuroblastoma, suggesting enhanced therapeutic strategies.